Paraguay's IPS Faces Critical Shortage of Autoimmune Disease Medications, Patients at Risk

ABC Color reports on a severe crisis at the Instituto de Previsión Social (IPS) in Paraguay, where hundreds of patients suffering from autoimmune diseases are facing a critical and total lack of essential medications. This situation, particularly the absence of drugs like Adalimumab and Methotrexate, is not new but has persisted under the current administration led by Isaías Fretes. The article highlights the grave health risks these patients endure due to the prolonged interruption of their treatments.

“

Hundreds of insured individuals face irreversible deterioration of their health due to the prolonged absence of essential drugs.

The Association of Patients with Psoriasis and Autoimmune Skin Diseases (APPEAP) warns that insured individuals are experiencing irreversible health deterioration. The lack of medication is described as a chronic crisis that has affected various administrations, leaving patients in a recurring state of vulnerability. Despite promises of restructuring the management of purchases and tenders, the reality in the pharmacies remains unchanged, according to the affected patients.

“

The lack of medication at the Social Welfare Institute (IPS) has reached a critical point for patients suffering from autoimmune diseases.

From a Paraguayan perspective, as reflected in ABC Color's reporting, this is a deeply concerning failure of the public health system to provide basic care. The article emphasizes the urgency of the situation, noting that APPEAP submitted a formal request to Fretes' office on May 4th detailing the critical need for these medications. The lack of a response or a clear timeline for restoring the supply underscores a systemic problem. The story is framed not just as a medical issue but as a failure of governance and a betrayal of the trust placed in the IPS by its beneficiaries. The emphasis on the irreversible damage and the impact on mental health adds a layer of human tragedy to the systemic failure.

“

The absence of these essential drugs not only implies the return of pain but also triggers severe outbreaks, progressive joint damage, and profound deterioration of the mental health of the insured.